News and research before you hear about it on CNBC and others. Request your 1-week free trial at StreetInsider Premium here.
DALLAS, May 11, 2021 OTC PR WIRE
Puration, Inc. (OTC Pink: PURA) and Alkame Holdings Inc. (OTC Pink: ALKM) today announced the completion of a formula for a new CBD-infused liquid sugar and plan to begin production soon.
In December 2020, PURA and ALKM announced plans to manufacture and test a CBD-infused liquid sugar, a CBD-infused pet food supplement, and a sexual wellness-flavored CBD lubricant.
ALKM is currently bottling PURA’s EVERx CBD sports water. As part of a growing partnership, PURA recently acquired one five percent stake in ALKM. In conjunction with this growing partnership, ALKM and PURA plan to direct the production of several new CBD-infused consumer goods.
PURA holds a license for a US patented cannabis extraction process that is supported by extensive university medical research. The license issued by NCM Biotech applies exclusively to beverages, food and cosmetics, among other things. NCM Biotech is focused on medical research and Puration has access to that research.
PURA and ALKM plan to announce the start of production of the new CBD-infused liquid sugar shortly, in addition to the advances made on the additional new products.
For more information on cleaning, see http://www.purationinc.com
For more information, visit www.alkameholdingsinc.com.
Alkame Holdings, Inc.
+1 (800) 861-1350
Disclaimer / Safe Harbor: This press release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the company’s current views with respect to future events that involve risks and uncertainties. These risks include, but are not limited to, the expectation that Alkame will generate significant sales, failure to meet the schedule or performance requirements of the company’s contracts, the company’s liquidity position, the company’s ability to win new contracts, the emergence of competitors with larger financial ones Resources and the Impact of Competitive Prices. Given these uncertainties, the forward-looking events discussed in this press release may not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.